Charles River to use credit facility borrowings to purchase HemaCare

By Sarah Lizee

Olympia, Wash., Dec. 16 – Charles River Laboratories International, Inc. plans use borrowings under its existing credit facility and cash to finance its $380 million acquisition of HemaCare Corp., according to a press release.

The proposed purchase price equates to $25.40 per HemaCare share.

The transaction is expected to close early in the first quarter of 2020, subject to receipt of regulatory approvals and other customary closing conditions.

Wilmington, Mass.-based Charles River Laboratories provides research and development services to pharmaceutical and biotechnology companies, government agencies and academic institutions. HemaCare is a blood products and services company based in Los Angeles.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.